Information Provided By: 
Fly News Breaks for April 16, 2018
HZNP
Apr 16, 2018 | 07:19 EDT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Horizon Pharma with a $17 price target after holding a conference call with two rheumatologists to discuss the market opportunity for Krystexxa. Both doctors agreed that Krystexxa is a very good drug and works best for a small group of refractory patients, which is all Horizon needs to meet or beat its peak sales forecast, Chen tells investors in a research note. The analyst believes there has been considerable debate as to whether the company can meet its forecasts.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
